Good evening :)
$
₹
N

NeOnc Technologies Holdings, Inc. Common Stock

NTHI

NASDAQ
N

NeOnc Technologies Holdings, Inc. Common Stock

NTHI

NASDAQ
$5.466.71% (+0.34)
$
₹
$5.466.71% (+0.34)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $131.6M the stock is ranked 4304

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-3.2
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.

Peers

Peers

Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
40.65
40.65
1Y Return
27.45%
27.45%
Buy Reco %
79.31
79.31
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
21.60
21.60
1Y Return
63.42%
63.42%
Buy Reco %
45.83
45.83
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
31.23
31.23
1Y Return
60.37%
60.37%
Buy Reco %
88.88
88.88
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
16.92
16.92
1Y Return
59.69%
59.69%
Buy Reco %
57.69
57.69
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
21.59
21.59
1Y Return
48.98%
48.98%
Buy Reco %
15.38
15.38

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
NeOnc Technologies Holdings, Inc. Common Stock -0-
Eli Lilly and Company40.6531.491.00
Johnson & Johnson21.607.171.69

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

0
-38
-5.6
-8.6
-15.5
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Revenue
Net Income
Financial YearQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Total Revenue000.040.0200.020.03000
Net Income-3.59-6.15-2.93-4.52-2.18-2.25-38-5.68-8.61-15.52
Net Profit Margin---6834.82%-22610.03%--11264.91%-95028.72%---
See CostsAll values in $ Million
Loading...